17 articles for SP Arneric
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Imidazo[4,5-c]pyridines as corticotropin releasing factor receptor ligands.
Bristol-Myers Squibb
Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands.
Bristol-Myers Squibb
Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice.
Abbott Laboratories
Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.
Abbott Laboratories
Novel 2-(2′-furo[3,2-b]pyridinyl) pyrrolidines: potent neuronal nicotinic acetylcholine receptor ligands
TBA
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.
Pfizer
Synthesis and structure-activity relationships of 5-substituted pyridine analogues of 3.
Abbott Laboratories
Structure-activity studies on a novel series of cholinergic channel activators based on a heteroaryl ether framework.
Abbott Laboratories
Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist.
Abbott Laboratories
Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties.
Abbott Laboratories
Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
Genentech
PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
Mitobridge
The discovery of carboline analogs as potent MAPKAP-K2 inhibitors.
Boehringer Ingelheim Pharmaceuticals